Dr. Musa Yilmaz
Claim this profileM D Anderson Cancer Center
Studies Myelodysplastic syndrome
Studies T-Lymphoblastic Leukemia/Lymphoma
3 reported clinical trials
7 drugs studied
Area of expertise
1Myelodysplastic Syndrome
TP53 positive
FLT3 positive
2T-Lymphoblastic Leukemia/Lymphoma
TP53 positive
FLT3 positive
Affiliated Hospitals
Clinical Trials Musa Yilmaz is currently running
Quizartinib + Decitabine + Venetoclax
for Acute Myeloid Leukemia
This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that is untreated or has come back (relapsed). Quizartinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as decitabine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving quizartinib and decitabine may work better at treating acute myeloid leukemia and myelodysplastic syndrome.
Recruiting2 awards Phase 1 & 2
CPX-351 + Quizartinib
for Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytarabine, works in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Quizartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The goal of this study is to learn if the combination of CPX-351 and quizartinib can help to control acute myeloid leukemia and myelodysplastic syndrome.
Recruiting1 award Phase 1 & 2
More about Musa Yilmaz
Clinical Trial Related6 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Musa Yilmaz has experience with
- Quizartinib
- Cladribine
- Cytarabine
- Idarubicin
- Liposome-encapsulated Daunorubicin-Cytarabine
- Decitabine
Breakdown of trials Musa Yilmaz has run
Myelodysplastic syndrome
T-Lymphoblastic Leukemia/Lymphoma
Acute Myeloid Leukemia
Relapse
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Musa Yilmaz specialize in?
Musa Yilmaz focuses on Myelodysplastic syndrome and T-Lymphoblastic Leukemia/Lymphoma. In particular, much of their work with Myelodysplastic syndrome has involved TP53 positive patients, or patients who are FLT3 positive.
Is Musa Yilmaz currently recruiting for clinical trials?
Yes, Musa Yilmaz is currently recruiting for 3 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Musa Yilmaz has studied deeply?
Yes, Musa Yilmaz has studied treatments such as Quizartinib, Cladribine, Cytarabine.
What is the best way to schedule an appointment with Musa Yilmaz?
Apply for one of the trials that Musa Yilmaz is conducting.
What is the office address of Musa Yilmaz?
The office of Musa Yilmaz is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.